Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. “We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Cannabis Law Report

MARCH 30, 2019

Epidiolex, manufactured by UK-based GW Pharmaceutical, was approved by the U.S. Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. Epidiolex was crafted as a treatment for two forms of childhood epilepsy.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study at a single site in the Netherlands to evaluate ANEB-001 in the inhibition of THC-induced effects. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Project CBD

OCTOBER 26, 2023

United Kingdom-based GW Pharmaceuticals has produced the world’s first approved cannabis-based medicines for the UK, US, and European markets, Sativex® and Epidiolex®. GW Pharmaceuticals’ research on glioblastoma multiforme (GBM) is important and promising. Note: In May 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals.]

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

Medical Marijuana Program Connection

MARCH 29, 2023

a research focused bio-pharmaceutical company today announced that the first subject. NEW YORK & GREENWOOD VILLAGE, Colo.–(BUSINESS –(BUSINESS WIRE)–ANANDA Scientific Inc., Read More

Clinical Trials 52

Clinical Trials Treatment Pharmaceutical Patients 52

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. Although both studies will enroll 25 patients initially, the U.S. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

SEPTEMBER 29, 2021

The company employs patented delivery technologies to make cannabinoids and other plant-derived compounds highly bioavailable, water soluble, and shelf-life stable, and it focuses on producing effective, premium quality pharmaceutical products. . & LOS ANGELES–(BUSINESS WIRE)– ANANDA Scientific Inc. ,

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Moreau CEO of Algernon Pharmaceuticals Inc. “We

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Veriheal

SEPTEMBER 18, 2020

Conventional forms of treatment are often accompanied by adverse side effects but there is hope for effective treatment with fewer side effects. . million of NWS Health funding for their Cannabinoid Therapeutics and Brain and Mind Centre to see if cannabidiol can be that effective treatment for spinal cord injury.

Treatment 98

Treatment Chronic Pain Research and Development CBD 98

The Cannigma

FEBRUARY 1, 2023

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. 7 The use of cannabis as a cancer treatment was popularized by Rick Simpson, a medical cannabis advocate. GBM is a rare but aggressive brain cancer with very limited treatment options.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

The Joint Blog

JULY 13, 2023

Classified as a neurological disorder, typical treatments include neuropathic painkillers that come with unpleasant side effects. Finding a natural alternative to these strong pharmaceuticals- one that doesn’t come with such downsides- could improve the lives of many sufferers. appeared first on The Joint Blog.

Treatment 47

Treatment CBD Clinical Trials Stress Management 47

NewsMunchies

DECEMBER 13, 2021

In the largest clinical trial to date, a new study conducted by the UK-based pharmaceutical company Compass Pathways shows that psilocybin or “magic” mushrooms can safely relieve depression. The trial included 233 patients from 10 countries in North America and Europe. In 2019, Denver became the first city in the U.S.

Clinical Trials 95

Clinical Trials Therapy Decriminalization Patients 95

Cannabis Law Report

FEBRUARY 14, 2020

a Canadian biotech firm, is entering Phase II clinical trials for two experimental treatments. According to its website, one trial involves an ibogaine-derived drug for treating opioid addiction. The other trial will test LSD microdosing as an ADHD treatment. Mind Medicine, Inc. ,

Microdosing 45

Microdosing Treatment Medicine Clinical Trials 45

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960).

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., Dr. Chapman received his M.D.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MYMD-1 is also showing promise as a potential treatment for post-COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

FloridaMarijuana.net

AUGUST 16, 2018

The Dementia Society of America attributes Dementia to rising healthcare costs as billions are spent each year for treatments and research. Pharmaceutical treatments for for Dementia often only target symptoms like pain or depression, but those medicines do not cure or prevent the disease.

Clinical Trials 184

Clinical Trials Marijuana Patients Pharmaceutical 184

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Info

OCTOBER 11, 2019

Cannabis & Dementia: New Study Explores Pot’s Potential for Treatment. In the decades since the medical marijuana movement began in earnest in the 1970s, cannabis has been anecdotally touted as an effective treatment for a variety of illnesses, including those impacting brain function, such as seizures, anxiety and depression.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

TheAnswerPage

JUNE 29, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59